Transient infrarenal aortic occlusion is a necessary accompaniment of most vascular reconstructions of the distal aorta and its terminal branches. In certain instances systemic hypotension follows restoration of extremity blood flow. Severe hypotension may occasionally compromise cardiac, cerebral and renal perfusion. Associated with this aortic declamping phenomenon is a severalfold increase in blood flow to the ischemic extremities. Although precise mechanisms are poorly defined, reactive hyperemia is in part responsible for the declamp hypotension.
Reliable, safe means to ameliorate declamp hypotension do not exist. Rigorous volume replacement, intraoperative administration of buffers, and vasopressors have been utilized to lessen this hazard of aortic surgery. Unfortunately, injudicious transfusions, fluid overloading, and systemic vasopressors may prove harmful to elderly patients with marginal cardiac and renal reserves. The present investigation was undertaken to determine what role the vasopressor prostaglandin F, (PGF,,) might have in the prevention of aortic declamp hyperemia and hypotension.
MATERIALS AND METHODS
Effects of PGF,, were documented in a canine model during consecutive clamping 'Presented: Ninth Annual Meeting of the Association for Academic Surgery, Minneapolis, Minn., November 14, 1975 and declamping trials. Individual animal! acted as their own control. Trials I and III (base line studies) involved infusions of phos phate buffer into the terminal aorta at the time of declamping. Trials II and IV (experi mental studies) differed in that PGF,, wa! added to the buffer.
Ten male mongrel dogs, weighing 17-35 kg, were studied. All animals wert anesthetized with sodium pentobarbital 3C mg/kg with supplemental doses adminis tered at 30 min intervals as needed. Dog: were intubated, mechanically ventilated, ant hydrated with lactated Ringers' (100 ml/hr' throughout the experiment. Animals wert systemically anticoagulated with sodiun heparin (100 units/kg iv). The aorta and iliac vessels were exposed through a midline ab. dominal incision. An adjustable clamp wa! placed about the infrarenal aorta for late] use in occluding this vessel. A polyethylene catheter for infusion purposes was advancec into the terminal aorta by way of the spermatic artery.
Left carotid artery and external jugular vein polyethylene catheters were positionec within the aorta and superior vena cava respectively. Electromagnetic square wave flow probes were placed on the right carotic and iliac arteries. Flow probes were zeroec electrically and mechanically with eacl study. A small catheter was inserted into thr right femoral vein for blood sampling. Sys temic arterial pressure, central venou! pressure, iliac and carotid artery blood flow! were recorded.
Following documentation of base lint 413 pressures and flows, the infrarenal aorta was clamped for 30 min (Trial I). At the conclusion of the clamp period, 12.5 ml of phosphate buffer (0.2 M, pH 6.5) were infused into the terminal aorta over a 30 set period prior to declamping. An additional 12.5 ml were infused during a 10 set period immediately following declamping. Pressure and blood flow were continuously monitored with restoration of flow to the lower extremities. A recovery period of 30 min was allowed, and the aorta was reclamped for a second 30 min (Trial II). Declamping technique terminating this second period of occlusion was similar in all respects to that of Trial I except for the addition of 20 pg/kg of prostaglandin F,, tromethamine salt to the 25 ml phosphate buffer solution. Identical recovery, clamp and declamp methodology was utilized for a second base line buffer infusion (Trial III) and with a second experimental PGF,, infusion (Trial IV). Hemodynamic measurements obtained during these studies, reflecting different declamp responses, were expressed as the mean f 1 SD, and analyzed by paired t test.
Femoral venous, central venous, and carotid artery blood pH, p0, and pC0, were documented prior to clamping, immediately before declamping and 30 set after declamping in five dogs. In five other animals prostaglandin B, (PGB,) and PGF,, activities were assayed in femoral vein and carotid artery blood samples. Specimens were collected immediately preceding clamping as well as 5 set and 5 min following declamping. PGB, levels were determined after conversion of prostaglandins A and E (PGA, PGE) to the former substance. Radioimmunoassay technique using specific antibodies for PGB, and PGF,, were used to quantitate prostaglandin activity (Clinical Assays Inc., Cambridge, Mass.).
RESULTS
Blood pressure and flow alterations observed in Trial I (first base line study) and Trial II (first experimental study) were markedly different (Table I ). Decreases in systemic arterial blood pressure with declamping and PGF,, infusions in Trial II averaged 11 f 7 mm Hg. This change in pressure was significantly less (P < 0.01) than the 27 f 8 mm Hg decrease occurring in earlier control (Trial I) studies.
Reactive hyperemia, reflected by maximum iliac artery blood flow following declamping, was diminished after administration of PGF,, (Trial II) in comparison to controls (Trial I). Peak flows in these instances were 208 l 104 and 334 f 143 ml/min, respectively. Differences in these hyperemic responses proved significant (P < 0.01). Marked hyperemic responses occurred immediately with declamping in control (Trial I) dogs (Fig. 1) . Blunting of the hyperemic response was evident (Fig. 2) following initial PGF,, infusion (Trial II). In certain cases hyperemia was attenuated by PGF, yet total blood flow to the ischemic extremities over 2-3 min approximated control flow volumes.
Decreases in peripheral blood flow (carotid artery) observed after initial aortic declamp- 'Data (rig/ml) expressed as mean and (range).
PGB and PGE activity, did not demonstrate significant increases of these substances as the experiment progressed from Trials I to IV (Table 2) . Elevated PGFza was documented in ischemic extremity effluent blood 5 set following declamping in experimental Trials II and IV, confirming high levels of this agent being delivered with aortic infusions (Table 3) . Measurements of PGF,, revealed increased venous levels from the ischemic extremity after the first PGF,,infusion of Trial II which persisted into Trial III. DISCUSSION Hemodynamic changes following aortic declamping are well known, yet exact mechanisms underlying these events are poorly understood. Declamp reactive hyperemia is thought to be primarily a reflex phenomenon rather than a sole consequence of local metabolic alterations [7] . The theory that increases in the vascular compartment of ischemic extremities cause pooling of blood away from the central circulation, is compatible with observations of increased canine hindlimb volumes following declamping [18, 191 . The basis for this change in the vascular compartment is unknown.
Prostaglandins are known for their vasoactive properties. The E and A series are primarily vasodepressors. Cardiovascular actions of the F series are complicated by species variation. PGF,, exerts a pressor action in dogs, rats, and man [4, 11, 12, 14-171. Most investigators agree that PGFB, causes constriction of canine capacitance vessels. DuCharme and his colleagues [4] observed that infusions of PGF, into perfused canine limbs increase peripheral resistance with constriction of smooth muscle of veins rather than arterioles. This increases venous return, right atria1 pressure and subsequently cardiac output. Others reported PGF,, to have a direct cardiac effect, increasing myocardial contractility and heart rate [6, 161. Although PGFza apparently has a primary effect on venous segments, it also has vasoconstrictive effects on other portions of the peripheral vascular bed. Increased vascular resistance, decreased blood flow and constriction of skeletal muscle arteries in response to PGF,, have been described [6, 8, 131 . Mechanisms of PGF,, action are poorly defined. This substance may directly stimulate vascular smooth muscle. PGF,, also interacts with the autonomic nervous system. Infusion of PGF, intra-arterially in subpressor concentrations enhances vasoconstrictor responses to sympathetic nerve stimulation in the canine hindlimb. PGF,, appears to enhance sympathetic transmission, by facilitating release of neurotransmitters at the nerve ending [l, 9, lo] .
The role of PGF,, pressor activity in humans remains unclear. Some investigators found PGF, given as a single intravenous injection (500 pg), increased arterial blood pressure, whereas when infused intravenously (4 pg/kg/min) and administered subcutaneously or intramuscularly (20 mg) it had no cardiovascular effect [ll] . Infused into superficial hand veins of man, PGF,, (200-500 ng/min) has a vasoconstrictor effect [2] . Subconstrictor dosages were not associated with depressor activity. In forearm arterial beds, PGF,, infusion (2-10 pg/min) increased blood flow [3] . Constrictor responses were noted in this later study at lower infusion levels (0.4-2 pg/min).
Present experimental observations. Initial infusions of PGF,, into the terminal aorta with aortic declamping attenuated the reactive hyperemic response and subsequent systemic arterial hypotension. PGFzu may constrict hindlimb capacitance vessels, thus limiting expansion of the ischemic extremities' vascular compartment. PGF,, may also enhance normal sympathetic vasoconstrictor activity accompanying declamp hypotension. Additional studies in isolated and denervated hindlimbs are needed to define exact JOURNAL OF SURGICAL RESEARCH: VOL. 20, NO. 5, MAY 1976 mechanisms of PGF,, action in this particular experimental model. An important finding of the present investigation was that PGF,, lessened declamp hypotension following its initial administration (Trial II), but was not subsequently effective (Trial IV). This phenomenon remains unexplained. Failure to effect changes with repeat PGFz,, infusions, despite documentation of high circulating levels of this prostaglandin within the ischemic extremity circulation, suggests a tachyphylactic response. Increased PGF2, levels during Trial III, when no PGF,, was administered, implies the existence of persistently elevated tissue levels of this substance. Studies by others [5] lend credence to the possibility that tachyphylaxis accounts for the nonresponsiveness to repeated PGF,, infusions. Accumulation of prostaglandin precursors following degradation of PGF2,, inducing production of E and A series prostaglandins was not supported by measurements of these prostaglandins in the present investigation.
Circulating PGF,, is inactivated with passage through the lungs. Infusions of PGF,, into the terminal aorta should thus have rather localized effects. Since PGF,, activity most consistently involves capacitance (venous) vessels, reversal or prevention of venodilation may be its primary action in the presently reported preparation. Pressor and venoconstrictor properties of PGF,, combined with pulmonary degradation of this substance, make it unique in regard to its cardiovascular actions. PGF,, may be of potential use in lessening adverse effects of aortic declamping, such as with sleeve resection of the infrarenal aorta or following temporary occlusions while revascularization of the splanchnic viscera or kidneys is being performed. PGF,, infusions would appear to be of limited value in situations requiring repeated administrations, such as with staged declamping of aortofemoral graft limbs. Further investigation is warranted to evaluate the efficacy of PGF,, in attenuating hyperemic responses and subsequent systemic arterial hypotension as a sequela of aortic declamping in the clinical setting.
